Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Safety Study in Patients With HER2 + Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male patient diagnosed with stage I-IV breast cancer~* HER2 positive breast cancer, defined by immunohistochemical staining for HER2 protein of 3+ intensity and/or amplification of the HER2 gene on fluorescence in situ hybridization (FISH) ≥ 2.0 on breast specimen or biopsy of a metastatic site~* LVEF \< 50% and ≥ 40% documented in echocardiogram done within the last 30 days~* HER2 therapy naïve or currently receiving non-lapatinib HER2 targeted therapy~* Patient receiving or planning to receive trastuzumab, trastuzumab with pertuzumab or ado-trastuzumab emtansine, for at least 3 months, alone or in combination with other systemic treatment or radiation~* Age ≥ 18 years~* Patient is willing and able to comply with protocol required assessments and procedures~Exclusion Criteria:~* Previous hospitalization due to documented heart failure in the last 12 months~* Current signs or symptoms of heart failure or ischemia~* History of arrhythmia requiring pharmacological or electrical treatment~* Concomitant use of anthracyclines or use of anthracyclines in the last 50 days~* Pregnant or lactating patients. Patients of childbearing potential must implement contraceptive measures during study treatment and for 7 months after last dose of treatment drug and must have negative urine or serum pregnancy test within 7 days prior to registration.~* History of significant neurologic or psychiatric disorders including psychotic disorders or dementia that would prohibit the understanding and giving of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- HER2 therapies, cardiac medications (Type: OTHER): Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:~* Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.~* Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.~* Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).